Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation

Therapy and Intervention

Idarucizumab for Dabigatran Reversal - Full Cohort Analysis

N Engl J Med.

Pollack CV Jr, Reilly PA, van Ryn J, Eikelboom JW, Glund S, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kam CW, Kamphuisen PW, Kreuzer J, Levy JH, Royle G, Sellke FW, Stangier J, Steiner T, Verhamme P, Wang B, Young L, Weitz JI

doi: 10.1056/

Atrial FibrillationTherapy and Intervention

Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial

Circ Cardiovasc Interv.

Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP

doi: 10.1161/CIRCINTERVENTIONS.119.008349.

Thrombosis and Stroke

Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants

J Am Coll Cardiol

Gómez-Outes A, Alcubilla P, Calvo-Rojas G, Terleira-Fernández AI, Suárez-Gea ML, Lecumberri R, Vargas-Castrillón E

doi: 10.1016/j.jacc.2021.04.061

Cardiac Arrest or DeathAtrial FibrillationMyocardial InfarctionThrombosis and StrokeTherapy and Intervention

Safety and Efficacy of Polymer-Free Biolimus A9-Coated Versus Bare-Metal Stents in Orally Anticoagulated Patients: 2-Year Results of the LEADERS FREE Oral Anticoagulation Substudy

JACC Cardiovasc Interv.

Carrié D, Menown I, Oldroyd K, Copt S, Talwar S, Maillard L, Morice MC, Teik LS, Lang I, Urban P

doi: 10.1016/j.jcin.2017.05.033.

Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study

Eur Heart J.

Godier A, Dincq AS, Martin AC, Radu A, Leblanc I, Antona M, Vasse M, Golmard JL, Mullier F, Gouin-Thibault I

doi: 10.1093/eurheartj/ehx403.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Benefits of Emergency Departments' Contribution to Stroke Prophylaxis in Atrial Fibrillation: The EMERG-AF Study (Emergency Department Stroke Prophylaxis and Guidelines Implementation in Atrial Fibrillation)

Stroke.

Coll-Vinent B, Martín A, Sánchez J, Tamargo J, Suero C, Malagón F, Varona M, Cancio M, Sánchez S, Carbajosa J, Ríos J, Casanovas G, Ràfols C, Del Arco C; EMERG-AF Investigators

doi: 10.1161/STROKEAHA.

Atrial FibrillationThrombosis and StrokeTherapy and Intervention

Dabigatran Etexilate: A Review in Nonvalvular Atrial Fibrillation.

Drugs.

Blair HA, Keating GM

doi: 10.1007/s40265-017-0699-z.

Atrial FibrillationHeart, Artery and Coronary Diseases

The Efficacy and Safety of the Use of Non-Vitamin-K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials

Circulation.

Bennaghmouch N, de Veer AJWM, Bode K, Mahmoodi BK, Dewilde WJM, Lip GYH, Brueckmann M, Kleine E, Ten Berg JM

doi: 10.1161/CIRCULATIONAHA.

Atrial Fibrillation

Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial